Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fexagratinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 known ✓ | P11362 | 12/20 | 0.75 |
| ▸ | FGFR2 known ✓ | P21802 | 3/20 | 0.47 |
| ▸ | FGFR3 known ✓ | P22607 | 2/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.75 |
| ▸ | RET | P07949 | 1/20 | 0.75 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.75 |
| ▸ | MARK3 | P27448 | 1/20 | 0.75 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.75 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.75 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.75 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.75 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.75 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.75 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.75 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.75 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.75 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.75 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.75 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.75 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-4547 SCHEMBL62926 | 1.00 | FGFR1 (0.75) | FGFR1NTRK1RETPDGFRBMARK3 | |
| Azd-4547 SCHEMBL19338066 | 1.00 | FGFR1 (0.75) | FGFR1NTRK1RETPDGFRBMARK3 | |
| SCHEMBL19338029 | 0.95 | FGFR1 (0.68) | FGFR1NTRK1RETPDGFRBMARK3 | |
| SCHEMBL65023 | 0.90 | FGFR1 (0.61) | FGFR1NTRK1RETPDGFRBMARK3 | |
| SCHEMBL15241153 | 0.90 | FGFR1 (0.61) | FGFR1NTRK1RETPDGFRBMARK3 | |
| SCHEMBL1921969 | 0.87 | FGFR1 (0.57) | FGFR1NTRK1RETPDGFRBMARK3 | |
| SCHEMBL64476 | 0.87 | FGFR1 (0.57) | FGFR1NTRK1RETPDGFRBMARK3 | |
| SCHEMBL1921961 | 0.87 | FGFR1 (0.57) | FGFR1NTRK1RETPDGFRBMARK3 | |
| Azd-4547 SCHEMBL22132858 | 0.86 | FGFR1 (1.00) | FGFR1NTRK1RETPDGFRBMARK3 | |
| Azd-4547 SCHEMBL15433983 | 0.86 | FGFR1 (1.00) | FGFR1NTRK1RETPDGFRBMARK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012052757-A1 | TUMOUR PHENOTYPE PATIENT SELECTION METHOD | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | WO | claimed |
| EP-2125748-B1 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2011-05-25 | — | — | EP | claimed |
| WO-2024031226-A1 | PHARMACEUTICAL COMPOSITION AND POLYMORPHIC SUBSTANCE OF FGFR INHIBITOR, AND PHARMACEUTICAL USE THEREOF | 无锡和誉生物医药科技有限公司 | 2024-02-15 | — | — | WO | disclosed |
| EP-3466948-B1 | FUSED PYRIMIDINOPIPERIDINE DERIVATIVE, AND MANUFACTURING METHOD AND APPLICATION THEREOF | SHANGHAI ALLIST PHARMACEUTICALS CO LTD (CN) | 2021-01-20 | — | — | EP | disclosed |
| US-20200385812-A1 | FGFR3 FUSION GENE AND PHARMACEUTICAL DRUG TARGETING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-12-10 | — | — | US | disclosed |
| US-10689705-B2 | FGFR3 fusion gene and pharmaceutical drug targeting same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-06-23 | — | — | US | disclosed |
| US-10544144-B2 | Fused pyrimidine piperidine cyclic derivative, preparation process and use thereof | SHANGHAI ALLIST PHARMACEUTICAL AND MEDICAL TECHNOL (CN) | 2020-01-28 | — | — | US | disclosed |
| US-10420764-B2 | Pharmaceutical formulation of N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-YL]-4-[(3R,5S)-3 ,5-dimethylpiperazin-1-YL] benzamide | ASTRAZENECA AB (SE) | 2019-09-24 | — | — | US | disclosed |
| US-10420764-B2 | Pharmaceutical formulation of N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-YL]-4-[(3R,5S)-3 ,5-dimethylpiperazin-1-YL] benzamide | ASTRAZENECA AB (SE) | 2019-09-24 | — | — | US | disclosed |
| US-10420764-B2 | Pharmaceutical formulation of N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-YL]-4-[(3R,5S)-3 ,5-dimethylpiperazin-1-YL] benzamide | ASTRAZENECA AB (SE) | 2019-09-24 | — | — | US | disclosed |
| EP-3087986-B1 | FGFR GATEKEEPER MUTANT GENE AND DRUG TARGETING SAME | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2019-09-18 | — | — | EP | disclosed |
| US-8129391-B2 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-2125748-B1 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | ASTRAZENECA AB | 2010-10-28 | — | — | US | disclosed |
| US-7737149-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2010-06-15 | — | — | US | disclosed |
| US-7737149-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2010-06-15 | — | — | US | disclosed |
| US-7737149-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2010-06-15 | — | — | US | disclosed |
| EP-2125748-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | AstraZeneca AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385812-A1 | FGFR3 FUSION GENE AND PHARMACEUTICAL DRUG TARGETING SAME | FGFR3, FGFR4, FGFR1 | FGFR1 3/4885FGFR2 4/4885FGFR3 1/4885 |
| US-10689705-B2 | FGFR3 fusion gene and pharmaceutical drug targeting same | FGFR3, FGFR4, FGFR1 | FGFR1 3/4885FGFR2 4/4885FGFR3 1/4885 |
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | FGFR1 823/4885FGFR2 939/4885FGFR3 1462/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | FGFR1 168/4885FGFR2 603/4885FGFR3 773/4885 |
| US-10420764-B2 | Pharmaceutical formulation of N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-YL]-4-[(3R,5S)-3 ,5-dimethylpiperazin-1-YL] benzamide | CASP5, PGA5, IL5 | FGFR1 3185/4885FGFR2 3085/4885FGFR3 3031/4885 |
| US-10544144-B2 | Fused pyrimidine piperidine cyclic derivative, preparation process and use thereof | FGFR1, FGFR4, FGFR2 | FGFR1 1/4885FGFR2 3/4885FGFR3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.